Managing High-Cost Therapies in Value-Based Care: Clinical and Policy Strategies

Pharmaceutical spending continues to rise faster than other healthcare costs—a trend driven by growing demand for GLP-1 medications for diabetes and obesity, and the arrival of high-cost innovations like gene and cell therapies for conditions such as sickle cell disease. At the same time, biosimilars for expensive biologics are creating new opportunities for cost savings.

In this breakout session, during the America’s Physician Groups Spring Conference 2025, Mark Shinmoto, PharmD, Chief Pharmacy Officer, Ventegra, moderated a panel discussion on how these developments affect prescribing and care delivery in value-based care models.

The panelists discuss clinical and operational considerations for access, procurement, and financial risk management, as well as key policy issues such as the Inflation Reduction Act’s Medicare drug price negotiations.

Reference
America’s Physician Groups. Breakout sessions. APG Spring Conference 2025 website. Accessed April 30, 2025. https://apg.cventevents.com/event/f303a3cf-4d66-4110-9e0d-3ca64c85d453/breakout-sessions-1?RefId=apgws25